Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cabaletta Bio, Inc. CABA
$12.60
-$0.5 (-3.96%)
На 18:02, 12 мая 2023
-32.54%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
372644490.00000000
-
week52high
13.34
-
week52low
0.59
-
Revenue
0
-
P/E TTM
-7
-
Beta
2.52615700
-
EPS
-2.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Overweight | 30 авг 2022 г. |
| Chardan Capital | Buy | Buy | 12 авг 2022 г. |
| Mizuho | Buy | Buy | 25 мая 2022 г. |
| Mizuho | Buy | Buy | 18 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 мар 2022 г. |
| Wells Fargo | Overweight | Overweight | 14 сент 2022 г. |
| Chardan Capital | Buy | Buy | 11 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 03 янв 2023 г. |
| Morgan Stanley | Overweight | Equal-Weight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Nichtberger Steven | A | 411600 | 411600 | 18 янв 2023 г. |
| Binder Gwendolyn | A | 176000 | 176000 | 18 янв 2023 г. |
| Das Arun | A | 150000 | 150000 | 18 янв 2023 г. |
| Gerard Michael | A | 112500 | 112500 | 18 янв 2023 г. |
| Marda Anup | A | 150000 | 150000 | 18 янв 2023 г. |
| Chang David J. | A | 150000 | 150000 | 18 янв 2023 г. |
| Nichtberger Steven | A | 986483 | 8127 | 19 окт 2022 г. |
| Nichtberger Steven | A | 978356 | 141873 | 18 окт 2022 г. |
| Binder Gwendolyn | A | 20000 | 20000 | 18 окт 2022 г. |
| Simon Mark | A | 7000 | 7000 | 18 окт 2022 г. |
Новостная лента
Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy
Zacks Investment Research
06 февр 2023 г. в 13:33
Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
31 янв 2023 г. в 10:15
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Cabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)
Seeking Alpha
25 янв 2023 г. в 06:29
Cabaletta Bio rallied hard in late FY22 with shares running up the page in near-linear fashion. The rally has extended to today's mark and we are looking to add to our position with another ticket of 500 shares.
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
05 янв 2023 г. в 08:00
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT (10:30 a.m. ET).
4 Drug Stocks That More Than Doubled This Year
Zacks Investment Research
30 дек 2022 г. в 10:32
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.